Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Annabelle Chow, Giulio Francia, Andrew Kouri, Christina Lee, John M. Ebos, Robert S. Kerbel and Urban Emmenegger
Affiliation: Sunnybrook Health Sciences Centre T2-054, 2075 Bayview Avenue, Toronto, Ontario M4N3M5, Canada.
Keywords: Autophagy, cyclophosphamide, low-dose metronomic chemotherapy, maximum tolerated dose chemotherapy.
Low-dose metronomic (LDM) chemotherapy was developed to overcome resistance to standard, maximum tolerated
dose (MTD) chemotherapy by shifting the primary treatment target from the highly adaptive tumor cells to diploid
endothelial cells. As such, LDM chemotherapy exerts potent antiangiogenic effects. However, it became rapidly apparent
that LDM chemotherapy is subject to resistance on its own, albeit by distinct mechanisms compared to MTD chemotherapy.
To address the lack of detailed knowledge on the mechanisms of resistance to LDM chemotherapy, we decided to
analyze the characteristics of prostate and breast cancer models with stable acquired resistance to LDM cyclophosphamide
(CPA). Whereas our studies suggest that compensatory angiogenic activity does not account for such resistance in a major
way, we identified low autophagic activity of tumor cells to be associated with resistance to LDM CPA. In addition, autophagy
inhibition by using chloroquine in the PC-3 human prostate cancer model, or genetically engineered autophagy deficiency
in immortalized baby mouse kidney cell tumors reversed the antitumor effects of LDM CPA. These findings contrast
with observations from others showing that autophagy inhibition might enhance the antitumor effects of vascular endothelial
growth factor (VEGF) targeted antiangiogenic therapy. On the other hand, the impact of autophagy modulation
in cancer is known to be highly context-dependent. Since a subset of malignancies is expected to have intrinsic autophagy
defects, assessing the autophagy status of tumors may become a tool to select patients for VEGF pathway targeted versus
LDM antiangiogenic therapy.
Rights & PermissionsPrintExport